section name header

Indications

REMS

Contraind./Precautions

Contraindicated in:

Use Cautiously in:

Adv. Reactions/Side Effects

Derm: flushing, rash.

GI: diarrhea, jaw pain, nausea, vomiting, appetite.

Hemat: anemia.

MS: arthralgia, myalgia.

Neuro: headache.

Resp: PULMONARY EDEMA.

Interactions

Drug-Drug:

Availability

Route/Dosage

Hepatic Impairment

US Brand Names

Uptravi

Action

Therapeutic Effects:

Classifications

Therapeutic Classification: vasodilators

Pharmacologic Classification:

Pharmacokinetics

Absorption: 49% absorbed following oral administration; food delays and extent of absorption.

Distribution: Highly protein bound.

Protein Binding: 99%.

Metabolism/Excretion: Hydrolyzed by carboxylesterase–1 to form active metabolite which contributes to pharmacologic activity. Also metabolized by CYP3A4 and CYP2C8 to form inactive metabolites. Primarily excreted in feces.

Half-life: 0.8–2.5 hr (selexipag); 6.2–13.5 hr (active metabolite).

Time/Action Profile

(blood levels)

ROUTEONSETPEAKDURATION
POunknown1–3 hr (selexipag); 3–4 hr (active metabolite)unknown

Patient/Family Teaching

Pronunciation

se-LEX-i-pag

Code

NDC Code*